Efficacy and Safety of Tralokinumab Across Racial Subgroups in Adults with Moderate-to-Severe Atopic Dermatitis: Post Hoc Analysis of Phase III Trials
ClinicalTrials.gov identifiers: NCT03131648 (registered 24 April 2017), NCT03160885 (registered 18 May 2017), NCT03363854 (registered 01 December 2017), and NCT03587805 (registered 03 July 2018).
Authors
- Melinda Gooderham (ORCID: https://orcid.org/0000-0001-8926-0113)
- Jonathan I. Silverberg (ORCID: https://orcid.org/0000-0003-3686-7805)
- Kenji Kabashima (ORCID: https://orcid.org/0000-0002-0773-0554)
- Emma Guttman‐Yassky (ORCID: https://orcid.org/0000-0002-9363-324X)
- Ben Esdaile
- Shannon Schneider
- Mads A. Røpke (ORCID: https://orcid.org/0000-0001-8922-5430)
- April Wang Armstrong (ORCID: https://orcid.org/0000-0003-0064-8707)
- Andrew F Alexis (ORCID: https://orcid.org/0000-0002-1351-9165)
- Rie von Eyben (ORCID: https://orcid.org/0000-0003-2355-8667)
- Leon Kircik (ORCID: https://orcid.org/0000-0002-0831-2151)
- Niels H. Bennike (ORCID: https://orcid.org/0000-0001-8718-6140)
- Britta C. Martel
- Andrew Blauvelt (ORCID: https://orcid.org/0000-0002-2633-985X)
- Tiffany Mayo (ORCID: https://orcid.org/0000-0002-7015-3817)
- Norito Katoh
Institutions
- University of California, Los Angeles (US)
- George Washington University (US)
- Queen's University (CA)
- Cornell University (US)
- Kyoto University (JP)
- University of Alabama at Birmingham (US)
- Kyoto Prefectural University of Medicine (JP)
- Maryland Department of Natural Resources (US)
- Probity Medical Research (CA)
- Whittington Health NHS Trust (GB)
- Leo Pharma (United States) (US)
- Leo Pharma (Denmark) (DK)
- Weill Cornell Medicine (US)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- American Journal of Clinical Dermatology
- Published
- 2025-10-21
- DOI
- https://doi.org/10.1007/s40257-025-00985-1
- Citations
- 1
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.00
Funders
- LEO Pharma